The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on ...

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...

On Friday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.59 which represents a slight increase of $0.22 or 3.45% from the prior close of $6.37. The stock opened at $6.33 ...

TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...

周三，贝尔德(Baird)调整了对Sage Therapeutics (NASDAQ:SAGE)股票的展望，将目标价从之前的13.00美元下调至9.00美元，同时维持对该股的中性评级。这一决定是在dalzanemdor用于阿尔茨海默病的2期LIGHTWAVE试验失败的公告之后做出的。试验的结果使投资者的全部注意力转向了该公司的另一个前景，即Zurzuvae。 LIGHTWAVE试验是Sage Th ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

周二，Oppenheimer调整了对Sage Therapeutics (NASDAQ:SAGE)的展望，将目标价从之前的10美元下调至9美元，同时维持对该股的"表现"评级。这一调整是在Sage宣布其药物dalzanemdor未能在评估阿尔茨海默病相关轻度认知障碍（AD-MCI）患者治疗的2期LIGHTWAVE研究中达到主要目标之后做出的。 LIGHTWAVE研究的结果被视为一个挫折，尽管在该药物 ...

On Wednesday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.49 which represents a slight increase of $0.06 or 0.93% from the prior close of $6.43. The stock opened at $6 ...